SCHEMBL4909568

SCHEMBL4909568

O=S(=O)(NC1CCN(Cc2cnccn2)CC1)c1ccc(CNc2nccc(Nc3ccc(F)cc3)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 6/20 0.48
BACE1 P56817 4/20 0.48
CCR3 P51677 1/20 0.43
CSF1R P07333 1/20 0.40
TYK2 P29597 1/20 0.40
ULK2 Q8IYT8 1/20 0.40
TBK1 Q9UHD2 1/20 0.40
HTR1A P08908 5/20 0.40
HTR7 P34969 5/20 0.40
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
ALOX12 P18054 1/20 0.39
MAPK1 P28482 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
JAK2 O60674 2/20 0.38
JAK1 P23458 2/20 0.38
ADORA3 P0DMS8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4687574 0.86 ACHE (0.49) ACHEBACE1CCR3HTR1AHTR7
SCHEMBL4649642 0.81 CA2 (0.46) ACHEBACE1MEN1NPC1LMNA
SCHEMBL4694201 0.79 ACVR1 (0.44) HTR1AHTR7MEN1NPC1LMNA
SCHEMBL4623805 0.77 HTR7 (0.49) HTR1AHTR7MEN1NPC1LMNA
SCHEMBL3303975 0.76 RAB9A (0.46) MEN1NPC1LMNAMAPTALOX12
SCHEMBL4623995 0.75 HTR1A (0.47) HTR1AHTR7MEN1NPC1LMNA
SCHEMBL3298093 0.73 MAPT (0.50) ACHEBACE1MEN1NPC1LMNA
SCHEMBL14020216 0.72 HTR1A (0.46) HTR1AHTR7MEN1NPC1LMNA
SCHEMBL4886241 0.71 HTR2A (0.47) ACHEBACE1HTR1AHTR7MEN1
SCHEMBL3304051 0.71 MAPT (0.47) MEN1NPC1LMNAMAPTALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors SANOFI-AVENTIS (FR) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors NFKBIA, IKBKB, IKBKE ACHE 3329/4885BACE1 2821/4885CCR3 4242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.